南新制药(688189) - 2022 Q1 - 季度财报

Revenue and Profit - Revenue for Q1 2022 was CNY 196,784,525.34, a decrease of 21.51% compared to the same period last year[5] - Net profit attributable to shareholders was CNY 11,813,068.13, down 52.13% year-on-year[5] - Basic earnings per share decreased by 52.13% to CNY 0.0844[5] - Total operating revenue for Q1 2022 was ¥196.78 million, a decrease of 21.5% compared to ¥250.72 million in Q1 2021[16] - Net profit for Q1 2022 was ¥6.98 million, a decline of 72.3% from ¥25.16 million in Q1 2021[17] - Basic and diluted earnings per share for Q1 2022 were ¥0.0844, down from ¥0.1763 in Q1 2021[17] Research and Development - R&D investment totaled CNY 12,163,330.21, a decline of 57.55% compared to the previous year[6] - R&D expenditure accounted for 6.18% of revenue, down 5.25 percentage points year-on-year[6] - Research and development expenses decreased significantly to ¥12.16 million in Q1 2022, down 57.5% from ¥28.65 million in Q1 2021[16] Cash Flow and Liquidity - The net cash flow from operating activities was negative at CNY -61,042,833.78, indicating a significant cash outflow[5] - Cash flow from operating activities showed a net outflow of ¥61.04 million in Q1 2022, an improvement from a net outflow of ¥68.94 million in Q1 2021[20] - Cash and cash equivalents at the end of Q1 2022 were ¥674.86 million, compared to ¥122.04 million at the end of Q1 2021[21] - The company raised ¥105 million in borrowings during Q1 2022, compared to ¥20 million in Q1 2021[21] - The company reported a net cash outflow from investing activities of ¥43.59 million in Q1 2022, an improvement from a net outflow of ¥125.18 million in Q1 2021[20] Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,095,741,507.86, a decrease of 1.65% from the end of the previous year[6] - The company's current assets totaled RMB 1,587,420,061.71, down from RMB 1,613,180,696.33, indicating a decrease of about 1.59%[12][13] - The company's cash and cash equivalents were RMB 674,858,261.75, a decrease from RMB 730,667,550.06, representing a decline of approximately 7.67%[12] - Short-term borrowings increased to RMB 439,188,222.20 from RMB 385,437,402.76, marking an increase of about 13.93%[13][14] - The total liabilities decreased to RMB 694,775,879.97 from RMB 736,886,724.25, reflecting a reduction of approximately 5.71%[14] - The company's total non-current assets were RMB 508,321,446.15, down from RMB 517,688,906.47, indicating a decrease of approximately 1.43%[13] - The company's inventory stood at RMB 57,764,296.23, down from RMB 61,425,161.64, indicating a decrease of approximately 5.39%[12][13] - The accounts receivable increased to RMB 626,970,399.98 from RMB 590,812,642.21, reflecting an increase of about 6.10%[12] Shareholder Information - Shareholders' equity attributable to shareholders increased by 0.85% to CNY 1,405,009,892.50[6] - The total number of common shareholders at the end of the reporting period was 7,110[10] - The company's equity attributable to shareholders rose to RMB 1,405,009,892.50 from RMB 1,393,196,824.37, an increase of about 0.84%[14] - The company's retained earnings improved to -RMB 62,690,123.16 from -RMB 74,503,191.29, showing a positive change in retained earnings[14] Market Conditions - The company experienced a decline in sales due to repeated COVID-19 outbreaks in multiple provinces[7]